All In Biotech

Drug Trial Radar · NCT05803941

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Aug 14, 2023

Primary completion

Jul 20, 2033

Study completion Jul 21, 2033

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.

Conditions

  • Prostate Cancer

Interventions

  • AAA617Drug

    Long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from parent interventional Novartis sponsored clinical trials.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and percentage of participants with selected Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: every visit up to 10 years after 1st dose of AAA617 received in parent treatment study

Locations

54 sites in 11 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Scottsdale, Arizona · Recruiting

  • St. Joseph Hospital

    Orange, California · Recruiting

  • Providence Saint Johns Health Ctr

    Santa Monica, California · Recruiting

  • University of Colorado

    Aurora, Colorado · Recruiting

  • Hartford Hospital

    Hartford, Connecticut · Recruiting

  • VA Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • University Cancer and Blood Center LLC

    Athens, Georgia · Recruiting

  • Parkview Research Center

    Fort Wayne, Indiana · Recruiting

  • Tulane Cancer Center

    New Orleans, Louisiana · Recruiting

  • Ochsner Clinic Foundation

    New Orleans, Louisiana · Recruiting

  • Corewell Health William Beaum Hosp

    Royal Oak, Michigan · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • University of Mississippi Med Ctr

    Jackson, Mississippi · Recruiting

  • Wash U School of Medicine

    St Louis, Missouri · Recruiting

  • Urology Cancer Center PC

    Omaha, Nebraska · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Cleveland Clinic Foundation

    Cleveland, Ohio · Recruiting

  • Univ of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • Univ of Texas Southwest Med Center

    Dallas, Texas · Recruiting

  • UT Health Science Center

    Houston, Texas · Recruiting

  • Onco Hemato Asso of SW Virginia

    Roanoke, Virginia · Recruiting

  • Novartis Investigative Site

    Linz, Austria · Recruiting

  • Novartis Investigative Site

    Vienna, Austria · Recruiting

  • Novartis Investigative Site

    Ghent, Belgium · Recruiting

  • Novartis Investigative Site

    Montreal, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Olomouc, Czechia · Recruiting

  • Novartis Investigative Site

    Prague, Czechia · Recruiting

  • Novartis Investigative Site

    Lyon, France · Recruiting

  • Novartis Investigative Site

    Essen, Germany · Recruiting

  • Novartis Investigative Site

    München, Germany · Recruiting

  • Novartis Investigative Site

    Rostock, Germany · Recruiting

  • Novartis Investigative Site

    Nijmegen, Gelderland, Netherlands · Recruiting

  • Novartis Investigative Site

    Maastricht, Limburg, Netherlands · Recruiting

  • Novartis Investigative Site

    Delft, South Holland, Netherlands · Recruiting

  • Novartis Investigative Site

    Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.